Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.
- Ingenia Therapeutics Nominated for Both the Prix Galien USA and the Inaugural Prix Galien Korea for Best StartupWATERTOWN, Mass., August 19, 2026--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, today announced that it has been nominated for the Prix Galien USA and the inaugural Prix Galien Korea, both in the Best Startup category by The Galien Foundation. The Galien Foundation is the premier global institution recognizing and awarding outstanding achievements of innovators in life sciences.
- Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company
- Kahn Swick & Foti, LLCCapricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26,...
- Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business UpdateREYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.
- Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership RoleKaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to a Securities Class Action Deadline on September 28, 2026.
- Aurora Cannabis Inc.Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis MarketAurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that it has acquired Internode Pharma Limited, a licensed importer and wholesaler, and...
- The Rosen Law Firm PAROSEN, A LEADING NATIONAL FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARDWHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14,...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of a Securities Class Action Deadline on October 5, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by...
- Flatiron HealthFlatiron Health Brings Three Research Acceptances to WCLC 2026NEW YORK, August 19, 2026--Flatiron Health today announced its presence at the IASLC 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, with three research acceptances highlighting real-world evidence that advances precision medicine and treatment optimization in non-small cell lung cancer (NSCLC). The presentations demonstrate how Flatiron's high-quality, longitudinal data reveals clinical insights that shape oncology decision-making acros
- ArcatoArcato Announces Phase 1 Clinical Trial Results and Closing of Fully Subscribed Financing Round--ARC-001 Gel demonstrates safety following third molar surgery-- --Exploratory analyses suggest durable analgesia as single dose ARC-001 Gel reduces post-operative pain within the first 24 hours and potentially for up to 1 week-- GREENVILLE, N.C., Aug. 19, 2026 -- Arcato...
- SafeSpace Global and BMRT Security Enter Binding Exclusive Agreement to Advance Detection of Concealed Weapons and Drugs for America’s Schools and Correctional FacilitiesUsing AI to spot the guns and drugs BEFORE they KILL.